Olesen G, Hansen K B, Kristensen J S
Medicinsk-haematologisk afdeling og patologisk institut, Arhus Universitetshospital, Arhus Amtssygehus.
Ugeskr Laeger. 1999 May 17;161(20):2943-8.
In a retrospective study we evaluate the treatment and outcome of 421 adults admitted to our department with acute myeloid leukemia (AML) during the 10 year period from 1985-1994. Younger patients (< or = 55 years) had a significantly better prognosis than elderly patients (> 55 years), partly because more younger patients had remission-induction therapy (81% versus 39%) and their complete remission (CR) rate was higher (69% versus 41%). In patients achieving CR the long-term survival (five years) was 40% for younger and 26% for elderly patients. Nineteen patients received autologous bone marrow transplantation (BMT) and eight an allogeneic BMT in first CR. Five patients treated with allogeneic BMT are still relapse-free, whereas autologous BMT, in comparison to conventional chemotherapy alone, did not improve the five-year relapse-free survival (29 versus 27%). Our data illustrate that in a non-selected material of AML patients the long-term survival (five years) has only slightly improved. The effect of autologous BMT cannot be evaluated in this retrospective setting.
在一项回顾性研究中，我们评估了1985年至1994年这10年间收治于我科的421例急性髓系白血病（AML）成年患者的治疗情况及预后。年轻患者（≤55岁）的预后明显好于老年患者（>55岁），部分原因是更多年轻患者接受了缓解诱导治疗（81%对39%），且其完全缓解（CR）率更高（69%对41%）。在达到CR的患者中，年轻患者的长期生存率（5年）为40%，老年患者为26%。19例患者在首次CR时接受了自体骨髓移植（BMT），8例接受了异基因BMT。5例接受异基因BMT治疗的患者仍无复发，而与单纯传统化疗相比，自体BMT并未改善5年无复发生存率（29%对27%）。我们的数据表明，在未经过选择的AML患者群体中，长期生存率（5年）仅略有提高。在这种回顾性研究中无法评估自体BMT的效果。
